Enlivex Therapeutics
ENLV
ENLV
23 hedge funds and large institutions have $4.12M invested in Enlivex Therapeutics in 2021 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 11 reducing their positions, and 3 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding
Funds holding: →
less ownership
Funds ownership: →
51% less capital invested
Capital invested by funds: $8.38M → $4.12M (-$4.27M)
64% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 11
Holders
23
Holding in Top 10
–
Calls
$664K
Puts
$457K
Top Buyers
| 1 | +$104K | |
| 2 | +$71K | |
| 3 | +$63K | |
| 4 |
CLOS
Compagnie Lombard Odier SCmA
1204 Geneva,
Switzerland
|
+$46K |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$39K |
Top Sellers
| 1 | -$678K | |
| 2 | -$359K | |
| 3 | -$171K | |
| 4 |
GG
Golden Green
Seneca,
South Carolina
|
-$151K |
| 5 |
Renaissance Technologies
New York
|
-$127K |